News | October 25, 2021
Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Subscribe To Our Newsletter & Stay Updated
